- Home
- ZYME vs RDWR Comparison
ZYME vs RDWR Comparison
Compare ZYME & RDWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYME
- RDWR
- Stock Information
- Founded
- ZYME 2003
- RDWR 1996
- Country
- ZYME United States
- RDWR Israel
- Employees
- ZYME 290
- RDWR N/A
- Industry
- ZYME Biotechnology: Pharmaceutical Preparations
- RDWR EDP Services
- Sector
- ZYME Health Care
- RDWR Technology
- Exchange
- ZYME Nasdaq
- RDWR Nasdaq
- Market Cap
- ZYME 956.0M
- RDWR 865.9M
- IPO Year
- ZYME 2017
- RDWR 1999
- Fundamental
- Price
- ZYME $13.88
- RDWR $21.83
- Analyst Decision
- ZYME Buy
- RDWR Hold
- Analyst Count
- ZYME 6
- RDWR 3
- Target Price
- ZYME $19.17
- RDWR $30.00
- AVG Volume (30 Days)
- ZYME 565.8K
- RDWR 128.3K
- Earning Date
- ZYME 03-05-2025
- RDWR 02-12-2025
- Dividend Yield
- ZYME N/A
- RDWR N/A
- EPS Growth
- ZYME N/A
- RDWR N/A
- EPS
- ZYME N/A
- RDWR N/A
- Revenue
- ZYME $62,199,000.00
- RDWR $266,880,999.00
- Revenue This Year
- ZYME $21.53
- RDWR $6.71
- Revenue Next Year
- ZYME N/A
- RDWR $6.58
- P/E Ratio
- ZYME N/A
- RDWR N/A
- Revenue Growth
- ZYME N/A
- RDWR N/A
- 52 Week Low
- ZYME $7.97
- RDWR $16.12
- 52 Week High
- ZYME $17.70
- RDWR $24.76
- Technical
- Relative Strength Index (RSI)
- ZYME 48.04
- RDWR 45.12
- Support Level
- ZYME $12.80
- RDWR $20.47
- Resistance Level
- ZYME $14.63
- RDWR $22.73
- Average True Range (ATR)
- ZYME 0.85
- RDWR 0.59
- MACD
- ZYME -0.04
- RDWR -0.04
- Stochastic Oscillator
- ZYME 25.29
- RDWR 49.45
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About RDWR Radware Ltd.
Radware Ltd provides cyber security and application delivery solutions. The company provides solutions for cloud, on-premises, and software-defined data centers (SDDC). The solutions of the company secure the digital experience by providing infrastructure, application, and network protection and availability services to enterprises globally. The business segments of the company are Radware's Core Business and The Hawks' Business. The company derives maximum revenue from Radware's Core Business. The company generates maximum revenue from the United States.